FDA grants 510(k) clearance to Omniscient’s brain mapping platform
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

FDA grants 510(k) clearance to Omniscient’s brain mapping platform

22 Jul 2021 (Last Updated July 22nd, 2021 16:04)

Quicktome uses Cloud computing and browser-based interfaces to simplify brain surgery processes for neurosurgeons.

FDA grants 510(k) clearance to Omniscient’s brain mapping platform
Quicktome allows neurosurgeons to visualise vital brain networks before surgery. Credit: Fakurian Design on Unsplash.

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Omniscient Neurotechnology’s (o8t) digital brain mapping platform, Quicktome, for neurosurgery.

A neurosurgical planning software, Quicktome integrates ‘connectomics’, which is the field of understanding brain connectivity, into routine neurosurgical planning.

These brain networks are vital for complex functions, including language, movement and cognition. Brain maps help in making informed surgical decisions to preserve and protect these networks.

Quicktome provides neurosurgeons with images, and therefore understanding, of a patient’s brain networks before performing a surgical procedure on the brain, which helps to lower surgical uncertainty.

Leveraging Cloud computing for high-volume data processing and browser-based interfaces, Quicktome could simplify the process of brain mapping for neurosurgeons.

The digital platform also aids multidisciplinary partnership in hospitals and offers better insight on a patient before and during a surgical procedure, Omniscient noted.

Furthermore, Quicktome assesses millions of data points obtained from a patient’s magnetic resonance imaging (MRI).

The platform is designed by neurosurgeons and data scientists and most of the analysis happens in the Cloud. This facilitates easy access to data on a desktop computer, enabling doctors to focus on procedures.

Apart from the US FDA clearance, Quicktome has obtained approval from Health Canada and the Therapeutic Goods Administration (TGA) of Australia.

Omniscient Neurotechnology CEO Stephen Scheeler said: “This is the first digital mapping platform designed to incorporate brain connectome data for neurosurgeons to improve patient outcomes.

“Until now, the tools that neurosurgeons have relied on have been no match for the brain’s complexity.

“Quicktome breaks information down into actionable insights to inform the impact each incision will have on the patient.”

A brain mapping company, Omniscient develops applications that can map and assess the networks formed by the electrical connections within an individual’s brain.

These insights aid doctors and scientists in understanding, testing and treating various complex neurological and mental ailments.